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ABSTRACT 
Background: Diabetes is positively associated with various cancers, but its relationship with tumors of 
the esophagus/esophagogastric junction remains unclear. 
Methods: Data were harmonized across 13 studies in the International Barrett’s and Esophageal 
Adenocarcinoma Consortium (BEACON), comprising 2,311 esophageal adenocarcinoma (EA) cases, 1,943 
esophagogastric junction adenocarcinoma (EGJA) cases, 1,728 Barrett’s esophagus (BE) cases, and 
16,310 controls. Logistic regression was used to estimate study-specific odds ratios (ORs) and 95% 
confidence intervals (CIs) for self-reported diabetes in association with EA, EGJA and BE. Adjusted ORs 
were then combined using random-effects meta-analysis. 
Results: Diabetes was associated with a 35% increased risk of EA (OR=1.35,95%CI:1.00–1.82; I2=48.8%), 
25% for EGJA (OR=1.25, 95%CI:1.03–1.52; I2=0.0%), and 27% for EA/EGJA combined 
(OR=1.27,95%CI:1.06–1.53; I2=34.9%). Regurgitation symptoms modified the diabetes-EA/EGJA 
association (pinteraction=0.04) with a 63% increased risk among participants with regurgitation 
(OR=1.63,95%CI:1.19–2.22), but not among those without regurgitation (OR=1.03,95%CI:0.74–1.43). No 
consistent association was found between diabetes and BE. 
Conclusions: Diabetes was associated with increased EA and EGJA risk, which was confined to individuals 
with regurgitation symptoms. Lack of an association between diabetes and BE suggests that diabetes 
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Condensed Abstract: The positive association between diabetes and esophageal and esophagogastric 
junction adenocarcinomas, but not BE, suggests that diabetes may be acting later in the carcinogenesis 
pathway.  
INTRODUCTION
Esophageal adenocarcinoma (EA) incidence has increased approximately 600% over the last 35 
years and, until the recent time period, was one of the most rapidly increasing cancer types in the 
United States (US) and other Western countries.1-3 The incidence of the anatomically-linked 
esophagogastric junction adenocarcinoma (EGJA) has also increased but less rapidly than EA.4 EA and 
EGJA are often considered as similar clinical entities because both are cancers at or near the 
gastroesophageal junction, have similar 5-year survival rates, and have comparable survival according to 
tumor stage.5 The only known potential precursor of EA/EGJA is Barrett’s esophagus (BE), which is 
associated with 10–40-times increased risk of EA/EGJA.6-8 Among individuals over the age of 50 years 
with gastroesophageal reflux disease (GERD), an estimated 10% also have BE.9 In the last 30 years, BE 
diagnosis increased 200–300% – independent of the number of gastrointestinal endoscopies 
performed.10-12
Obesity has previously been associated with BE13 and EA/EGJA.14 Two hypotheses have been 
proposed for the association between obesity and these tumors: 1) mechanical effects on the integrity 
of the esophagogastric junction including both direct somatic pathways, whereby central adiposity 
promotes the development of GERD which may then promote BE development,15 and indirect pathways, 
whereby diabetes induces mechanophysiological changes in the esophagus which may then promote 
the development of tumors,16 or 2) systemic metabolic alterations due to obesity increasing the levels of 
various hormones, including insulin, which may promote the development of BE or the progression of 
BE to cancer.17
Type 2 diabetes, which accounts for 95% of diabetes diagnoses,18 is often characterized by 
hyperinsulinemia and has been associated with a higher risk of various cancers, including malignancies 
of the liver, pancreas, endometrium, colorectal, breast and bladder.19, 20 Diabetes has been increasing in 
prevalence, and 12% of adults in the US18, 19 and 9% worldwide21 have prevalent diabetes. However, the 
association between diabetes and EA/EGJA remains understudied,22 with several studies suggesting an 
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association between diabetes and BE, with inconsistent results.31-35 Thus, we utilized studies from the 
International Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON, 
http://beacon.tlvnet.net/) to examine the associations of diabetes with risk of BE and EA/EGJA. 
MATERIALS AND METHODS
Study Design and Population
This study draws on the resources of BEACON, which, as previously described,36 was formed to 
facilitate pooling of resources from epidemiologic studies focused on the Barrett’s 
esophagus/esophageal adenocarcinoma continuum. In brief, this consortium was formed in 2005 by an 
international group of investigators to provide an open epidemiologic research forum for all completed 
or ongoing population-based studies of EA or BE.36 Thusly, this consortium allows for pooled analysis of 
individual-level data and avoids reliance on only published data. The present study pools information 
from 13 BEACON studies that included assessment of diabetes: three cohort and six case-control studies 
examining EA or EGJA (Supplementary Table S1); and one cohort and five case-control studies 
examining BE (Supplementary Table S2). Two studies included examination of both BE and EA/EGJA.37, 38 
Of the nine EA and EGJA studies, six were conducted in North America, two in Europe, and one in 
Australia. Of the six BE studies, three were conducted in North America, two in Europe, and one in 
Australia. Detailed descriptions of recruitment procedures can be found in study-specific publications.32, 
37-48 Institutional review board or research ethics committee approval was obtained by each sponsoring 
institution. 
Cases were categorized as EA, EGJA, or BE. We also combined EA and EGJA cases (EA/EGJA). 
Case eligibility was determined by the parent studies, based on endoscopy, pathology, and/or medical 
records. Histology and site determination were based on radiology, surgery, pathology, and/or 
endoscopy reports or linkage with a cancer registry. 
For the cohort studies, a nested case-control approach was employed. A case to control ratio of 
1:2 was used in the Netherlands Cohort Study (NLCS); 1:4 in the National Institutes of Health-AARP Diet 
and Health Study (NIH-AARP); and 1:8 in the Kaiser-Permanente Multiphasic Health Checkup Study 
(MHC). The EA/EGJA case-control studies recruited population-based controls, whereas the BE case-
control studies recruited population-based and/or endoscopy controls.
The analytic study population was restricted to non-Hispanic whites, as there were few cases 
from non-white ethnic groups (EA/EGJA: 60 black, 127 Hispanic, 77 other race or ethnic group; BE: 54 
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1,943 EGJA cases, 1,728 BE cases, and 16,310 controls. Participants had a mean age of 60 years and 
were more likely to be male (73.5%).
Exposure
To provide comparable data from the parent studies, we harmonized responses from the nine 
EA/EGJA and six BE parent studies for diabetes and potential covariates. To assess diabetes, most used a 
variation of the question “Did a doctor ever tell you that you had diabetes?” Prior studies have shown 
that the agreement between self-reported diabetes compared to medical record review ranges from 83-
98%.49-51 Additionally, the Newly Diagnosed Barrett’s Esophagus Study (NDB) also measured fasting 
glucose to determine undiagnosed diabetes, which resulted in 11 additional participants classified with 
diabetes (7.6% of total participants with diabetes in the NDB study).33 Only one study, Factors 
Influencing the Barrett’s/Adenocarcinoma Relationship Study (FINBAR),37 specifically asked about type 1 
versus type 2 diabetes. For the studies with age at diabetes diagnosis available (five EA/EGJA studies and 
two BE studies), a diagnosis after age 30 was assumed to be type 2 diabetes, as most type 1 diabetes is 
diagnosed peri-puberty. Additionally, 95% of diabetes is type 2.18 Duration of type 2 diabetes in years 
was examined as a continuous variable for tests of linear trends and categorized as 0.5-3, >3-5, >5-
10, and >10 years.23, 24 BEACON study responses for other covariates were harmonized and have been 
previously described for cigarette smoking,52, 53 alcohol consumption,54, 55 body mass index (BMI),13, 14 
waist circumference,13, 14 non-steroidal anti-inflammatory drug use,56, 57 and reflux symptoms.58 
Statistical Analyses
For our pooled study, we conducted a two-step analytic approach. First, we used multivariable 
unconditional (for case-control studies) or conditional (for matched case-control studies nested within 
cohorts) logistic regression to estimate study-specific odds ratios (ORs) and 95% confidence intervals 
(CIs) for the association between diabetes and EA, EGJA, combined EA/EGJA, or BE. Then, the study-
specific estimates were pooled using meta-analytic techniques.59 Estimates generated with fixed-effects 
and random-effects models were similar. Given that the latter are more robust to study heterogeneity,60 
we only present random-effects models. Between-study heterogeneity was assessed using a χ2 test 
based on the Q statistic and the I2 statistic (where 0% indicates no heterogeneity and larger values 
indicate increasing heterogeneity between studies).61 While investigating differences across studies 
includes quantification of heterogeneity, the most critical aspects are ensuring that the studies are 
comparable in clinical and methodologic aspects,61 as BEACON was designed. To demonstrate that there 
was no selection bias (i.e., “publication bias”), funnel plots were visually inspected for asymmetry and 
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test.63 To determine the influence of individual studies, we conducted a meta-influence analysis, 
whereby we excluded one study at a time and re-estimated the summary effect estimates. 
Potential confounders64 included age (at diagnosis for cases and interview for controls), sex, 
education (<high school, high school graduate/vocational school, college graduate for BE studies; study-
specific education categories for EA and EGJA studies), cigarette smoking (ever, never; current, former, 
never; duration in years; and pack-years), alcohol consumption (drinks per day), BMI (kg/m2), waist 
circumference (cm), non-steroidal anti-inflammatory drug use (ever/never), and fruit and vegetable 
consumption (servings per day). Age, sex, and BMI were included a priori as confounders. For the other 
potential confounders, if the log OR changed by ≥10% due to variable elimination in any parent study, 
the variable was considered a confounder and retained in all models.64 Final models included age 
(continuous), sex, smoking status (ever, never), and BMI (continuous). 
We considered effect measure modification by sex, BMI (<25/≥25 kg/m2), smoking (ever/never), 
and age (<60/≥60 years). Additionally, report of heartburn (retrosternal burning), regurgitation, and any 
reflux symptoms (i.e., heartburn or regurgitation) were assessed as potential modifiers (ever/never). 
Heartburn symptoms were defined as burning or aching pain behind the breastbone/sternum, and 
regurgitation symptoms were defined as a sour taste in the mouth resulting from regurgitation of acid, 
bile or other stomach contents. In the NLCS, reflux symptoms were defined as any report of heartburn, 
hiatal hernia, esophagitis, gastritis, or an esophageal or stomach/duodenal condition treated with 
antacids or H2 antagonists. For analyses of effect measure modification, we used a pooled dataset of 
individual-level data with additional adjustment for parent study, instead of the two-step meta-analytic 
approach. Departures from the multiplicative null were evaluated through stratification and by using 
likelihood ratio tests from nested logistic regression models.64 Departures from the additive null were 
approximated by calculating the relative excess risk due to interaction (RERIOR = OR11 – OR10 – OR01 + 1; 
null hypothesis = 0), synergy index (SOR = (OR11 – 1)/((OR10 – 1) + (OR01 – 1)); null hypothesis = 1), and the 
attributable proportion due to interaction, which assumes a causal relationship (APOR = RERIOR/OR11; null 
hypothesis = 0).65, 66 
Sensitivity Analysis
As not all studies assessed heartburn and regurgitation symptoms, we conducted additional 
effect measure modification models that were restricted to studies that ascertained both of these 
exposures. For EA/EGJA, this included the Australian Cancer Study (ACS), FINBAR, and the Los Angeles 
County Multi-ethnic Case-control Study (LAS). For BE, this included FINBAR, NDB, the Study of Digestive 
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examined heartburn and regurgitation symptoms categorized as “none”, “weekly”, and “≥weekly”, the 
latter of which we term “recurrent” symptoms. Analyses were conducted using SAS version 9.4 (SAS 
Institute, Cary, NC) and Stata version 14.0 (StataCorp LP, College Station, TX).
RESULTS
Descriptive characteristics of cases and controls are shown in Table 1. Both EA and EGJA cases 
were more likely than the population-based controls to be smokers (79.2 and 79.7 vs. 63.6%) and had a 
slightly higher BMI (28.0 and 27.4 vs. 26.4 kg/m2). In the six studies with symptoms available, EA and 
EGJA cases were more likely to have reported reflux symptoms than controls (58.1 and 58.8 vs. 45.2%). 
In the BE studies, mean BMI was comparable between the BE cases and population-based controls (27.8 
vs. 27.4 kg/m2, respectively) but lower than the endoscopy-based controls (29.1 kg/m2). However, BE 
cases had a higher proportion of smokers (67.7%) compared with both control groups (60.7 and 61.5%, 
respectively). Prevalence of reflux symptoms was similar between BE cases and endoscopy controls 
(56.3 vs. 66.5%), but lower in population-based controls (24.6%).
The associations between diabetes and risk of EA/EGJA are shown in Table 2 and Figure 1. In 
multivariable analyses, a diabetes diagnosis was associated with a 34% increased risk of EA (OR=1.34, 
95% CI: 1.00–1.80; I2=48.8%), a 27% increased risk of EGJA (OR=1.27, 95% CI: 1.05–1.55; I2=0.0%), and a 
30% increased risk of EA/EGJA (OR=1.30, 95% CI: 1.06–1.58; I2=34.9%). Results were robust in the meta-
influence analysis, dropping one study at a time (Supplementary Figure S1). Selection bias of studies 
included in BEACON was unlikely as assessed examination of the funnel plots and by the Begg and 
Mazumdar’s (p>0.05) and Egger’s tests (p>0.05) (Supplementary Figure S3). When the analysis was 
restricted to individuals with self-reported or suspected type 2 diabetes (i.e., classifying individuals with 
a self-report of diabetes after age 30 years as type 2), compared to individuals without a diabetes 
diagnosis, diabetes was associated with a non-significant 17% increased risk of EA, EGJA, and EA/EGJA 
(Table 2). There was no trend between duration of type 2 diabetes and EA (ptrend=0.3), EGJA (ptrend=0.5), 
or EA/EGJA (ptrend=0.3). 
As shown in Table 3, the association between diabetes and risk of EA/EGJA was modified by 
regurgitation symptoms (pinteraction=0.04). Diabetes was associated with a 63% increased risk of EA/EGJA 
among individuals with regurgitation symptoms (OR=1.63, 95% CI: 1.19–2.22), but there was no 
association between diabetes and EA/EGJA among individuals without regurgitation symptoms 
(OR=1.03, 95% CI: 0.74–1.43). When cross-classified, the group with diabetes but without regurgitation 
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regurgitation but without diabetes was at a 2-times increased risk of EA/EGJA (OR=2.10, 95% CI: 1.81–
2.45), and the group with both regurgitation and diabetes was at a 3.4-times increased risk of EA/EGJA 
(OR=3.42, 95% CI: 2.49–4.69), each compared with the referent group of individuals without diabetes or 
regurgitation (data not tabulated). Regurgitation and diabetes provided a relative excess risk due to 
interaction (RERI) of 1.29 (95% CI: 0.22–2.36, p=0.02), a synergy index of 2.14 (95% CI: 1.23–3.72, 
p=0.007), and an attributable proportion due to interaction of 0.38 (95% CI: 0.16–0.59, p=0.001) in 
relation to the risk of EA/EGJA. Results were similar when we restricted the analyses to only those 
studies with information on both symptoms of heartburn and regurgitation (Supplemental Table S3). 
When we examined regurgitation and heartburn symptoms categorized as “none”, “<weekly” (non-
recurrent), and “≥weekly” (recurrent), there was also evidence of effect modification in relation to 
EA/EGJA (pinteraction=0.009, Supplemental Table S4), with the increased risk observed among individuals 
reporting non-recurrent (<weekly) regurgitation symptoms (OR=1.77, 95% CI: 1.17–2.70) and no 
associations among individuals reporting recurrent (≥weekly) regurgitation symptoms (OR=1.10, 95% CI: 
0.64–1.90) or reporting no symptoms (OR=0.84, 95% CI: 0.57–1.24). There was little evidence of effect 
modification of the diabetes-adenocarcinoma association by BMI, smoking, and sex (Table 3). 
The association between diabetes and BE is shown in Table 4 and Figure 2. There was no 
consistent association between diabetes and BE when compared to population-based controls 
(OR=0.87, 95% CI: 0.67–1.13; I2=18.3%) or endoscopy controls (OR=0.93, 95% CI: 0.71–1.20; I2=0.0%). 
Results were robust in the meta-influence analysis, dropping one study at a time (Supplementary Figure 
S2). Selection bias of studies included in BEACON was unlikely as assessed examination of the funnel 
plots and by the Begg and Mazumdar’s (p>0.05) and Egger’s tests (p>0.05) (Supplementary Figure S4). 
Similarly, when results were restricted to individuals with self-reported or suspected type 2 diabetes, 
there was no association between diabetes and BE (Table 4). No trend was found between duration of 
type 2 diabetes and BE compared to population-based (ptrend=0.7) or endoscopy controls (ptrend=0.8). 
There was no evidence of effect measure modification between diabetes and reflux symptoms, sex, 
BMI, smoking, or age in relation to BE (Table 5 and Supplemental Table S5).
DISCUSSION
In this pooled analysis of 13 studies from BEACON, diabetes was associated with a 27–34% 
increased risk of EA/EGJA but not BE. In the studies of EA/EGJA, we also report a synergistic interaction 
between diabetes and regurgitation symptoms. Compared to those without diabetes or regurgitation, 
individuals with diabetes and regurgitation had a 3.4-times increased risk of EA/EGJA. Finally, we did not 
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The increased risk of EA/EGJA, but not BE, associated with diabetes suggests that diabetes may be acting 
later in the carcinogenesis pathway.
The current study is the largest study of EA or EGJA reported to date with information on 
diabetes status of study participants. One prior meta-analysis examined the association between 
diabetes and esophageal cancer (all histologic types), but only three of the studies included in the meta-
analysis were specific for EA.22 The other studies included were either esophageal squamous cell 
carcinoma, the other primary type of esophageal cancer which has a different etiology,67 or a mixture of 
histological subtypes. A number of previous studies have suggested that diabetes increases the risk of 
EA,23-28 while others showed no association.29-31 Of the three prior studies showing no association 
between diabetes and EA, one is included in the current pooled analysis.30 Another was conducted in 
the UK Clinical Practice Research Datalink, which is a large electronic medical record database.31 It is 
unclear why our results would be discrepant, but a further study included herein from Northern Ireland 
and Ireland (FINBAR) also found little to no association between diabetes and EA, suggesting potential 
geographic heterogeneity. The third and final previously published study that reported no association 
between diabetes and EA/EGJA included fewer cases (n=311) than we report herein (n=1,249).29 
Moreover, it was conducted in a population of US veterans with GERD which provided an unusually high 
prevalence of diabetes (36% in EA/EGJA cases, 32% in controls) compared with our study (12% in 
EA/EGJA cases, 6% in controls), as well as other factors including male sex (90%),68 overweight or obesity 
(78%),69 and ever smoking (68%),70 which reduces the generalizability of its findings.
In the current study, we report a synergistic interaction between diabetes and symptomatic 
regurgitation but not overall reflux symptoms (defined as heartburn or regurgitation symptoms). Three 
prior studies that assessed this interaction reported that reflux did not modify the diabetes-EA/EGJA 
association.23, 28, 31 However, two of these studies defined GERD as coded in medical records and were 
not able to stratify by heartburn or regurgitation symptoms.28, 31
Few studies have assessed the association between diabetes and BE, and the results have been 
inconsistent.31-35 Two of the previous studies, which are included in the current analysis, found little to 
no association between diabetes and BE.32, 33 Similarly, two studies conducted within the UK Clinical 
Practice Research Datalink offer little evidence for any association between diabetes and BE.31, 34 
However, after further adjustment for BMI, smoking, and GERD, Iyer et al. reported a 50% increased risk 
of BE associated with diabetes.34 Another study using SEER-Medicare data reported diabetes was 
associated with an increased risk of BE when compared with population controls, but not endoscopy 
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of the control group. If diabetes conferred no increased risk of progression from BE to adenocarcinoma, 
then the diabetes-EA/EGJA association would be approximately equal to that observed for diabetes-BE. 
However, as we observed an association between diabetes and EA/EGJA, but not BE, this suggests that 
diabetes may influence the risk of progression of BE to cancer. The synergistic interaction observed 
between diabetes and regurgitation symptoms also indicates that diabetes may be promoting 
progression from reflux or BE to EA/EGJA. 
Our pooled study is the first to indicate that the association between diabetes and EA/EGJA may 
be strongest among those with regurgitation symptoms. Reasons for diabetes and regurgitation 
synergistically increasing risk of EA/EGJA are not completely understood. However, putative 
mechanisms of diabetes-induced mechanophysiological changes may explain our observation,16 
including impaired lower esophageal sphincter relaxation71, 72 and dysfunction of the esophageal body 
(e.g., dysfunctional peristalsis) which may result in decreased motility,73, 74 antral spasms and 
gastroparesis75 providing more opportunities for reflux. Diabetes and hyperglycemia may also be 
associated with gastroparesis via diabetic (vagal) neuropathy,76 which is thought to result from 
modification of proteins by advanced glycation end-products leading to development of atrophy and 
degeneration of nerve fibers.16 
The interaction between diabetes and regurgitation but not heartburn symptoms may be 
explained by diabetic neuropathy; GERD patients with diabetes report less frequent acid regurgitation 
symptoms than GERD patients without diabetes,77, 78 while prior research indicates little to no decline in 
frequency of heartburn symptoms in GERD patients with diabetes.77, 78 Symptomatic regurgitation 
compared to heartburn is associated with a higher proximal extent of the liquid reflux component,79 
which has been utilized as a proxy measure of increased contact time between the esophageal mucosa 
and gastric refluxate.80 Assuming asymptomatic regurgitation is also more severe than heartburn, 
individuals with diabetes may be experiencing regurgitation symptoms less frequently due to diabetic 
neuropathy, but they may still be exposed to high levels of gastric refluxate if they are experiencing 
asymptomatic regurgitation. When we stratified on frequency of reflux symptoms, we found that the 
association between diabetes and EA/EGJA was primarily confined to individuals with non-recurrent 
regurgitation symptoms, suggesting that they may be experiencing asymptomatic reflux. These putative 
mechanisms aptly explain why we may observe a synergistic interaction between diabetes and 
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This study has several limitations. First, few BEACON studies assessed age at diabetes diagnosis 
or differentiated between type 1 and type 2 diabetes. Thus, to improve our assessment of type 2 
diabetes, we restricted our analysis to diabetes diagnosed after age 30 years as a proxy for type 2 
diabetes. Therefore, some degree of misclassification is likely, as type 1 diabetes can be diagnosed at 
any age. However, type 1 diabetes is most commonly diagnosed under age 20 and only accounts for 5% 
of all diabetes diagnoses;18 thus, misclassification of exposure is likely to be minimal. In addition, the 
little information on diabetes medication usage collected in the parent BEACON studies was of 
insufficient detail to examine. For example, one questionnaire asked participants if they had diabetes 
treated with insulin injections or if they had diabetes treated with tablets and/or diet.40, 41 Thus, it was 
not possible to accurately discern whether individuals were treated with tablets (and if so, what type), 
dietary changes, or did not receive treatment for diagnosed diabetes. Moreover, different anti-diabetic 
drugs are heterogeneous with respect to their cancer effects, and hence detailed information would be 
needed to assess effects on EA/EGJA. We also did not have information on degree of diabetes control, 
such as hemoglobin A1c. The majority of participants in BEACON were males of European descent, and 
therefore the results may not be generalizable to women or non-Europeans. That said, the 
overwhelming majority of individuals that develop EA and EGJA are white males;81 thus, these findings 
are still likely relevant to those at highest risk of developing these cancers. Finally, the current study 
included populations with both high and low prevalence of diabetes, in the controls this ranged from 
2.7% in Kaiser-Permanente Multiphasic Health Checkup Study (MHC)43 to 39.8% in the Houston 
Barrett’s Esophagus Study (VAT).32 However, we did not observe substantial between-study 
heterogeneity in the risk estimates, and results were robust in the meta-influence analysis. Additionally, 
this study included case-control and cohort studies. The diabetes diagnoses case-control studies may be 
subject to differential misclassification of exposure, whereby cases could be diagnosed incidentally 
when undergoing testing for a cancer diagnosis and controls would not be diagnosed. However, 
stratifying the results by case-control versus cohort studies resulted in nearly identical estimates for 
junctional adenocarcinomas (data not shown). 
The large sample size of our pooled study improved the precision of our effect estimates and 
allowed us to investigate potential effect modification by reflux symptoms, sex, BMI, smoking, and age. 
However, the number of cases for the stratified analyses was still relatively small. Additionally, utilizing 
BEACON resources, we were able to examine the precursor lesion of BE and invasive cancer, allowing us 
to speculate about the possible timing of when diabetes may have an effect in the BE-adenocarcinoma 
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estimates because we were able to use individual-level, uniform definitions for the exposure and the 
covariates across all parent studies (in contrast to the standard meta-analytic approach, which must rely 
on published group information only). 
In summary, our large pooled study provides evidence that diabetes is associated with an 
increased risk of EA/EGJA, but not BE, suggesting that diabetes may influence the risk of progression of 
BE to cancer. The increased risk for EA/EGJA was primarily confined to individuals with regurgitation 
symptoms, which acted synergistically with diabetes. Future studies should evaluate whether the 
synergistic association between diabetes and regurgitation symptoms persists in individuals with well-
controlled diabetes and elucidate mechanisms that underlie these observations. 
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Figure Legends.
Figure 1. Forrest plot of the relationship between diabetes and (A) esophageal adenocarcinoma, (B) 
esophagogastric junction adenocarcinoma, and (C) all esophageal and esophagogastric junction 
adenocarcinomas, by random effects model adjusted for age, sex, smoking (never, ever), and body mass 
index (continuous).
Figure 2. Forrest plot of the relationship between diabetes and Barret155t’s esophagus, versus (A) 
population controls and (B) GERD/endoscopy controls, by random effects model adjusted for age 
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Table 1. Descriptive characteristics of the pooled study population, Barrett’s and Esophageal Adenocarcinoma Consortium.











Age, years (SD) 60.5 (9.0) 60.5 (7.9) 57.5 (11.8) 62.3 (8.8) 62.0 (8.7) 60.1 (9.4)
Sex, n (%)
   Male 1,256 (72.7) 2,073 (73.2) 1,231 (73.1) 2,059 (89.2) 1,666 (86.0) 8,127 (68.6)
   Female 472 (27.3) 757 (26.8) 452 (26.9) 250 (10.8) 272 (14.0) 3,713 (31.4)
   Missing 0 0 0 0 0 1
Cigarette Smoking, n (%)
   Never 547 (32.3) 1,103 (39.3) 624 (38.5) 471 (20.8) 383 (20.3) 4,187 (36.4)
   Ever 1,147 (67.7) 1,700 (60.7) 995 (61.5) 1,792 (79.2) 1,505 (79.7) 7,324 (63.6)
   Missing 34 27 64 46 50 330
Body Mass Index, kg/m2 (SD) 27.8 (4.8) 27.4 (5.1) 29.1 (5.8) 28.0 (4.9) 27.4 (4.7) 26.4 (4.4)
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Table 2. Adjusteda odds ratios (ORs) and 95% confidence intervals (CIs) for associations between 
diabetes and esophageal and esophagogastric junction adenocarcinomas.




No 1,942 7,577 Referent
Yes 238 554 1.34 (1.00–1.80) 48.8 0.05
Type 2 Diabetes
b
No 928 5,444 Referent
Yes 147 544 1.17 (0.90–1.51) 0.0 0.8
Duration of type 2 diabetes
0.5-3 years 38 174 1.01 (0.67–1.52) 0.0 0.8
>3-5 years 14 39 1.31 (0.67–2.56) 0.0 0.7
>5-10 years 47 148 1.33 (0.89–1.97) 0.0 0.9
>10 years 45 183 1.22 (0.78–1.90) 19.6 0.3
Diabetes
No 1,622 6,584 Referent
Yes 184 463 1.27 (1.05–1.55) 0.0 0.6
Type 2 Diabetes
b
No 972 4,918 Referent
Yes 123 459 1.17 (0.91–1.51) 0.0 0.6
Duration of type 2 diabetes
0.5-3 years 35 138 1.29 (0.84–1.99) 0.0 0.7
>3-5 years 11 39 1.12 (0.45–2.74) 27.2 0.2
>5-10 years 32 119 1.31 (0.68–2.54) 43.7 0.1
>10 years 42 163 1.12 (0.66–1.92) 40.7 0.1
Diabetes
No 3,564 10,498 Referent
Yes 422 735 1.30 (1.06–1.58) 34.9 0.1
Type 2 Diabetes
b
No 1,900 6,699 Referent
Yes 270 734 1.17 (0.96–1.42) 0.0 0.7
Duration of type 2 diabetes
0.5-3 years 73 250 1.12 (0.82–1.54) 0.0 0.6
>3-5 years 25 39 1.08 (0.60–1.93) 4.2 0.4
>5-10 years 79 202 1.37 (1.00–1.88) 0.0 0.7




All Esophageal and Esophagogastric Junction Adenocarcinoma
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bAvailable for ACS, BKW, FINBAR, LAS, LEO, and a subset of NIH-AARP.
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Table 3. Adjusteda odds ratios (ORs) and 95% confidence intervals (CIs) for interaction between diabetes 
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Reflux Symptoms
b
No 766 3,202 Referent 66 157 1.24 (0.91–1.72)
Yes 1,094 2,082 Referent 155 130 1.49 (1.15–1.94) 0.4
Regurgitation
c
No 562 1,409 Referent 69 118 1.03 (0.74–1.43)
Yes 767 1,186 Referent 121 84 1.63 (1.19–2.22) 0.04
Heartburn
b
No 931 3,553 Referent 94 183 1.35 (1.02–1.78)
Yes 916 1,717 Referent 125 104 1.46 (1.09–1.95) 0.7
Sex
Male 3,128 7,135 Referent 380 552 1.25 (1.08–1.44)




1,110 4,445 Referent 66 174 1.17 (0.86–1.58)
≥25 kg/m2 2,470 6,012 Referent 356 560 1.28 (1.10–1.49) 0.6
Smoking
Never 740 3,818 Referent 80 240 1.34 (1.01–1.77)
Ever 2,840 6,639 Referent 342 494 1.23 (1.05–1.43) 0.6
Age
<60 years 925 2,966 Referent 71 134 1.32 (1.02–1.72)
≥60 years 1,650 3,859 Referent 257 349 1.23 (1.05–1.43) 0.6
All Esophageal and Esophagogastric Junction Adenocarcinoma
aAdjusted for age (continuous), sex, smoking (never, ever), and body mass index (continuous).
bAvailable for ACS, FINBAR, MHC, LAS, NLCS, and PMCC.
cAvailable for ACS, FINBAR, LAS, and PMCC. 
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Table 4. Adjusteda odds ratios (ORs) and 95% confidence intervals (CIs) for the association between 
diabetes and Barrett’s esophagus, compared to population-based and endoscopy controls, respectively.




No 1,325 2,438 Referent
Yes 158 301 0.87 (0.67–1.13) 18.3 0.3
Type 2 Diabetes
b 
No 709 913 Referent
Yes 116 144 1.00 (0.64–1.56) 49.3 0.1
Duration of type 2 diabetes
0.5-3 years 35 27 1.74 (0.73–4.15) 48.3 0.1
>3-5 years 19 25 0.85 (0.46–1.60) 0.0 0.5
>5-10 years 25 31 0.98 (0.44–2.20) 42.4 0.2
>10 years 21 42 0.58 (0.33–1.01) 0.0 0.6
Diabetes
No 816 1,195 Referent
Yes 130 268 0.93 (0.71–1.20) 0.0 1.0
Type 2 Diabetes
b 
No 709 1006 Referent
Yes 116 239 0.97 (0.73–1.28) 0.0 1.0
Duration of type 2 diabetes
0.5-3 years 35 55 1.11 (0.52–2.36) 48.3 0.1
>3-5 years 19 34 1.05 (0.55–2.00) 0.0 0.5
>5-10 years 25 58 0.77 (0.45–1.31) 0.0 0.5
>10 years 21 44 0.90 (0.51–1.57) 0.0 0.5
Population-based Controls
Endoscopy Controls
aAdjusted for age (continuous), sex, smoking (never, ever), and body mass index (continuous).
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Table 5. Adjusteda odds ratios (ORs) and 95% confidence intervals (CIs) for interaction between diabetes 
and other risk factors and Barrett’s esophagus, compared to population-based and endoscopy controls, 
respectively.
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bAvailable for FINBAR, NDB, and SDH.
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Figure 1. Forrest plot of the relationship between diabetes and (A) esophageal adenocarcinoma, (B) 
esophagogastric junction adenocarcinoma, and (C) all esophageal and esophagogastric junction 
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Figure 2. Forrest plot of the relationship between diabetes and Barret155t’s esophagus, versus (A) 
population controls and (B) GERD/endoscopy controls, by random effects model adjusted for age 
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